NCI National Clinical Trials Network (NCTN) Program Guidelines

More documents

Recommendations

Info

PART 4: Appendices Section V – Important Definitions, Abbreviations, & NIH/NCI URLs OD Office of the Director at the NCI OEWG Operational Efficiency Working Group OGA Office of Grants Administration OHRP Office for Human Research Protections OPEN Oncology Patient Enrollment Network ORI Office of Research Integrity PD Program Director PHS Public Health Service PI Principal Investigator PIO Protocol and Information Office (in CTEP) PMB Pharmaceutical Management Branch (in CTEP) PRC Protocol Review Committee (in CTEP – also known as NCI/DCTD PRC) RAB Regulatory Affairs Branch (in CTEP) RRP Radiation Research Program (in DCTD) RSS Regulatory Support System (in CTSU) SDMC Statistics and Data Management Center SOP Standard Operating Procedure SPORE Specialized Programs of Research Excellence SRO Scientific Review Officer URL Uniform Resource Locator (internet address of resource) Page 222 of 241
Part 4: Appendices – VI. Sample Table of Contents for PHS398 Applications for the Key Components of the NCTN VI. Sample Table of Contents for PHS 398 Application (Example: Network Group Operations Center) SECTION I Face Page Description, Project/Performance Sites, Senior/Key Personnel, Other Significant Contributors, & Human Embryonic Stem Cells Research Grant Table of Contents Detailed Budget for Initial Budget Period & Budget for Entire Proposed Period of Support � Plus Common Budget Outline � Accrual Input by Member Institution/Sites Used to Generate Part of Network Group Ops Center Budget Budget Pertaining to Consortium/Contractual Arrangements Biographical Sketch Program Director(s)/Principal Investigator(s) (Not to exceed four pages each) � Other Biographical Sketches (Not to exceed four pages each – See instructions) � Other Support Information (Submitted only as “Just-in-Time” Information, not with application) Resources � Include Required Tables (See Pages 195 to 201) � List of Member Institutions/Participating Sites of Network Group (See Page 238) � Include Key SOPs � 1 Page Justifications for Restricted Categories of Funding for Legacy Studies (See Page 104) – limited to follow-up for certain categories of legacy trials & sites, bridge funding for tumor banking activities, and special data management for select legacy studies with large resource needs SECTION II Research Plan Checklist Appendix Specific Aims (including Impact Statement) Research Strategy Sections A. Operations Center Overview (up to 12 pages) B. Clinical Trial Development Program (up to 30 pages) C. Member Site Accrual Program (up to 12 pages) D. Operational Management (up to 12 pages) E. Program for Collaborations and Participation in Collective Management (up to 12 pages) Bibliography and References Cited Protection of Human Subjects Inclusion of Woman and Minorities Targeted/Planned Enrollment Table Inclusion of Children Vertebrate Animals Select Agent Research Multiple Program Director/Principal Investigator (PD(S)/PI(S)) Leadership Plan Consortium/Contractual Arrangements Letters of Support (e.g., Consultants) Resource Sharing Plans Page 223 of 241
Page 1 and 2:
NATIONAL CANCER INSTITUTE NATIONAL
Page 3 and 4:
NCTN Program Guidelines Table of Co
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
PART 1: Overview of NCTN Program Se
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
PART 1: Overview of the NCTN Progra
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
PART 2: Submission of Competing New
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
PART 2: Submission of New/Competing
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172: PART 2: Submission of New/Competing
Page 187 and 188: PART 3: Submission of Non-Competing
Page 189 and 190: TYPE OF STUDY PART 3: Submission No
Page 191 and 192: PART 3: Submission Non-Competing Ap
Page 193 and 194: PART 3: Submission Non-Competing Ap
Page 195 and 196: PART 4: Appendices Section II - Req
Page 201 and 202: Participating Site Member Category
Page 211 and 212: PART 4: Appendices Section IV - Cos
Page 217 and 218: PART 4: Appendices Section V - Impo
Page 219 and 220: PART 4: Appendices Section V - Impo
Page 221: PART 4: Appendices Section V - Impo
Page 225 and 226: Part 4: Appendices - VII. Model for
Page 227 and 228: Part 4: Appendices - VII. NCTN Prog
Page 233 and 234: Part 4: Appendices - IX. Common Bud
Page 235 and 236: Part 4: Appendices - IX. Common Bud
Page 237 and 238: Part 4: Appendices - VII. Accrual I
Page 239 and 240: Part 4: Summary of Updates to Guide
Page 241: Part 4: Summary of Updates to Guide
show all

NCI National Clinical Trials Network (NCTN) Program Guidelines

Create successful ePaper yourself

Delete template?

Save as template?